12 Oct 2020

Full-year EBITDA guiding in focus

Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%

- Thomas Lorck
- 11 pages

Aker BioMarine will release its Q3/20 results on Friday 30 October. We have not made any changes to our estimates in this preview, and reiterate our adj. EBITDA projection of USD 27.4m. Our main attention will be towards AKBM’s 2020 adj. EBITDA guiding of USD 80-90m, as well as the progress of KORI sales. We stick to our Buy rating as well as our NOK 185 target price ahead of the Q3/20 report.

Sign up to access

Get access to our full offering from over 30 providers

Full-year EBITDA guiding in focus

Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%

Published: 12 Oct 2020
Author: Thomas Lorck
Pages: 11

Aker BioMarine will release its Q3/20 results on Friday 30 October. We have not made any changes to our estimates in this preview, and reiterate our adj. EBITDA projection of USD 27.4m. Our main attention will be towards AKBM’s 2020 adj. EBITDA guiding of USD 80-90m, as well as the progress of KORI sales. We stick to our Buy rating as well as our NOK 185 target price ahead of the Q3/20 report.